Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.
about
ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancerIn vitro comparative models for canine and human breast cancersCurrent status and patent prospective of animal models in diabetic researchUse of rodents as models of human diseasesMucin-based targeted pancreatic cancer therapyOncolytic virotherapy of canine and feline cancerFetal Microchimerism in Cancer Protection and Promotion: Current Understanding in Dogs and the Implications for Human HealthClinical trials of immunogene therapy for spontaneous tumors in companion animals.Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculatureDog models of naturally occurring cancerCanine cancer immunotherapy studies: linking mouse and human.Re-evaluate the effect of hyperbaric oxygen therapy in cancer - a preclinical therapeutic small animal model studyHypermethylation of the DLC1 CpG island does not alter gene expression in canine lymphomaMicroarray analysis of differentially expressed genes of primary tumors in the canine central nervous system.Global gene expression profiling: a complement to conventional histopathologic analysis of neoplasia.Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesionsA pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology.Development and characterization of 5 canine B-cell lymphoma cell linesCopy number abnormalities in sporadic canine colorectal cancers.Genetically engineered mouse models for drug development and preclinical trials.Characterization of the canine mda-7 gene, transcripts and expression patterns.The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.Optimized mouse model for the imaging of tumor metastasis upon experimental therapy.Affinity of the alpha4-beta1 integrin-targeting peptide LLP2A to canine lymphoma.Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer.Onco-epidemiology of domestic animals and targeted therapeutic attempts: perspectives on human oncology.Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphomaAnimal models and therapeutic molecular targets of cancer: utility and limitations.Genomic instability and telomere fusion of canine osteosarcoma cells.Y-chromosome DNA is present in the blood of female dogs suggesting the presence of fetal microchimerism.Breed-specific incidence rates of canine primary bone tumors--a population based survey of dogs in NorwayMolecular imaging biomarkers of resistance to radiation therapy for spontaneous nasal tumors in caninesLigand-independent canonical Wnt activity in canine mammary tumor cell lines associated with aberrant LEF1 expressionComparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors.Spontaneous transformation of murine epithelial cells requires the early acquisition of specific chromosomal aneuploidies and genomic imbalances.Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma.Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.Cancer in rodents: does it tell us about cancer in humans?
P2860
Q24810389-A6650EFF-F8F8-4552-937C-95DE96C496D3Q26752714-208D1EBC-41DC-42FE-AF60-6D3CD8C5A176Q26799371-03829ADD-F0E3-4514-8C8B-7B82B4BC68F1Q26822856-9E360000-774D-4F42-A304-D728A6A84359Q26861761-B837B1FB-7AAD-48F0-AD17-31B73369D62DQ27008306-561B7230-DF00-417C-9DB0-D41329907C32Q27025003-57F161BE-BB2C-4938-A214-E509E9B99A89Q27692032-9F1FCC95-597D-4510-A0CC-E0CAAFAE892AQ28475128-540DED63-B7D1-46F7-B457-C714B204E1EFQ28742833-07206BE7-B8DE-4E62-9C50-7527B74C6CF8Q30239893-7C4B266A-139A-4352-ABBC-7CDC284E57CFQ30461128-CBA8F315-CE86-4EE3-B7C5-EFCB6ECE18F9Q30884853-41FBE801-4FDC-4C05-8B6F-8E95EE23E879Q33222868-3D6069CA-5DAA-4E13-80A2-CF28FB151670Q33227605-9DB8F719-2EBB-46C7-A6C1-14507F71D936Q33562282-5F4F23F4-75A9-475C-BD30-BF7624437560Q33586974-80BC4593-119B-420E-95DE-C8EF21B3089AQ33600546-F4127D4A-E6A8-441D-B245-0B195679DB19Q33736545-9AE3FC4F-C80F-412E-A4DD-DBF6BC9F3972Q34039768-E3407F9E-6EEA-422D-91E9-32607601CB14Q34040220-932BC53B-0E85-4EC9-9BAA-B9C44E3FD15EQ34044072-577A7F87-267D-42F7-8DA6-0706F9BCA86DQ34071624-0082EC8C-70DA-4399-8902-563F0DDDC613Q34158053-F2A43166-55E6-45B9-B756-8F39FFAB6067Q34168530-2D779A72-EE2A-4941-A673-2CA84595E8A8Q34333794-102BBB2F-BE33-4BAE-BAB5-6DFBE1EE3CD3Q34373001-E926C2D9-4619-44FA-AE6E-8C1587C6E3EFQ34386828-C13E2144-167F-4081-99F6-0E841344BCB7Q34391518-DD1803E6-4D01-4920-9FEE-DE323195365CQ34826830-3052B50C-08C1-4F87-A4F6-625B18EF33E2Q35067482-AFD6AD1D-DECC-4518-A861-2F2D9FDBAE31Q35165000-7862E9B8-4FA2-49E9-B77E-FF9CF992DCD6Q35179788-BFE31E25-FC56-4EE9-8026-CE7495B64CD1Q35661959-EAA20CB0-EB59-48CE-A262-0D8733C6DC52Q35748478-7DE686C7-BF08-43A0-A9C4-F8F4B5DA3D50Q35799695-244F61EB-515B-42EE-B399-87FC82E4C570Q35822083-6B8425FE-DEAD-46BE-A65A-2D52A0253AEDQ35895339-1E4448C3-6287-4ED4-9672-1ACF1B395699Q36099082-D0931C79-49B6-42E9-8391-F97774549908Q36272962-95905337-6BD6-416A-B78E-E44C978459B6
P2860
Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Spontaneous and genetically en ...... nical cancer drug development.
@ast
Spontaneous and genetically en ...... nical cancer drug development.
@en
type
label
Spontaneous and genetically en ...... nical cancer drug development.
@ast
Spontaneous and genetically en ...... nical cancer drug development.
@en
prefLabel
Spontaneous and genetically en ...... nical cancer drug development.
@ast
Spontaneous and genetically en ...... nical cancer drug development.
@en
P1476
Spontaneous and genetically en ...... nical cancer drug development.
@en
P2093
P304
P356
10.1016/J.EJCA.2003.11.031
P577
2004-04-01T00:00:00Z